About Syngene International Ltd
Syngene International Ltd is a contract research and manufacturing organization (CRMO). It offers these services for pharmaceutical, nutrition, animal health, and speciality chemical companies. The company provides integrated research, development, and manufacturing services globally. The company falls under the Healthcare Services sector. Syngene specifically focuses on the Contract Research & Manufacturing Services (CRAMS) subsector.
Initiated in 1993, Syngene has been in business for many years. The company is headquartered in Bangalore, Karnataka, India. Syngene was promoted by Biocon Ltd, with Dr. Kiran Mazumdar-Shaw playing a pivotal role in its establishment and growth. Also, he serves as the non-executive chairman of the company. The company is guided by an experienced board of directors. The managerial promoters of the company include:
The promoter shareholding of the company stands at 54.72%. Biocon remains the principal promoter of the company, holding a 54.45% stake in the company.
The main services offered by Syngene include integrated drug discovery services, dedicated R&D centres and biologics manufacturing. It also offers small molecule development manufacturing and clinical development services. The company operates state-of-the-art research facilities that cater to global pharmaceutical giants.
Syngene is among the leading players in India's CRAMS sector. However, it is not the top player in terms of market capitalization. The company has established itself as one of the most respected names in the industry, with a strong global client base. This includes Bristol Myers Squibb, Amgen, and GSK.
The company's registered office is located at Biocon Park, Bommasandra Industrial Area, Phase IV, Bangalore - 560099, Karnataka. The registrar and transfer agent for Syngene is KFin Technologies Limited.
The company's international footprint is primarily demonstrated through its impressive client roster. This includes several global pharmaceutical giants. Bristol Myers Squibb is one of the world's largest pharmaceutical companies. It has had a long-standing relationship with Syngene, operating a dedicated research facility in Bangalore. The partnership of these companies began in 2007 and has grown significantly. This showcases Syngene's ability to meet international quality standards and regulatory requirements.
Syngene International has collaboration with Amgen and another major global biotechnology company. This further strengthens its international credentials. The company operates a dedicated R&D centre for Amgen, providing integrated drug discovery and development services. This partnership demonstrates Syngene's capability to handle complex research projects and meet the exacting standards of international clients.
The company's relationship with GlaxoSmithKline (GSK) represents another significant international partnership. Through this collaboration, Syngene provides various research and development services. This contributes to GSK's global drug discovery and development programs. These partnerships with leading pharmaceutical companies have helped Syngene build a strong reputation in the global CRAMS market.
Syngene's international operations are supported by its state-of-the-art facilities in India that conform to global standards. The company's research and manufacturing facilities are certified by international regulatory authorities. These authorities include the US FDA and EMA (European Medicines Agency), which enables the company to serve its clients worldwide. This regulatory compliance has been crucial in attracting and retaining international clients.
The company has also developed expertise in various therapeutic areas that are relevant to global markets. These therapeutic areas include oncology, cardiovascular, diabetes, and inflammatory diseases. This broad therapeutic coverage allows Syngene to cater to diverse international client requirements and participate in global drug discovery and development programs.
Syngene's international business model is built on providing integrated services across the drug discovery and development value chain. The company offers end-to-end solutions from early-stage research to commercial manufacturing. These solutions appeal to international clients looking to outsource their R&D and manufacturing needs. This comprehensive service offering has helped Syngene secure long-term contracts with international clients.
The company's scientific talent pool comprises highly qualified researchers and scientists. Many of these researchers and scientists have international exposure and experience, which further strengthens the company's ability to serve global clients. This expertise allows Syngene to undertake complex research projects and deliver results that meet international standards.
Syngene International's success in building a strong international presence can be attributed to its focus on quality, regulatory compliance, comprehensive service offerings, and strong client relationships. The company has successfully positioned itself as a reliable partner for global pharmaceutical and biotechnology companies. This is evidenced by its long-term partnerships with industry leaders like Bristol Myers Squibb, Amgen, and GSK.
Plus, the company is committed to maintaining high-quality standards and investing in cutting-edge facilities. This suggests that it will continue to strengthen its position in the global CRAMS market. The company's international focus has helped to grow its business. Also, this has also contributed to establishing India as a preferred destination for pharmaceutical research and manufacturing services.
Initiated in 1993, Syngene has been in business for many years. The company is headquartered in Bangalore, Karnataka, India. Syngene was promoted by Biocon Ltd, with Dr. Kiran Mazumdar-Shaw playing a pivotal role in its establishment and growth. Also, he serves as the non-executive chairman of the company. The company is guided by an experienced board of directors. The managerial promoters of the company include:
- Jonathan Hunt
- Sibaji Biswas
- Catherine Rosenberg
- Kush Parmar
The promoter shareholding of the company stands at 54.72%. Biocon remains the principal promoter of the company, holding a 54.45% stake in the company.
The main services offered by Syngene include integrated drug discovery services, dedicated R&D centres and biologics manufacturing. It also offers small molecule development manufacturing and clinical development services. The company operates state-of-the-art research facilities that cater to global pharmaceutical giants.
Syngene is among the leading players in India's CRAMS sector. However, it is not the top player in terms of market capitalization. The company has established itself as one of the most respected names in the industry, with a strong global client base. This includes Bristol Myers Squibb, Amgen, and GSK.
The company's registered office is located at Biocon Park, Bommasandra Industrial Area, Phase IV, Bangalore - 560099, Karnataka. The registrar and transfer agent for Syngene is KFin Technologies Limited.
International Base of the Company
Syngene International Ltd. has established itself as a prominent global contract research and manufacturing organization. The company serves its clients across many continents. Since its start in 1993, the company has systematically built its international presence by focusing on delivering high-quality research, development, and manufacturing services to pharmaceutical and biotechnology companies worldwide.The company's international footprint is primarily demonstrated through its impressive client roster. This includes several global pharmaceutical giants. Bristol Myers Squibb is one of the world's largest pharmaceutical companies. It has had a long-standing relationship with Syngene, operating a dedicated research facility in Bangalore. The partnership of these companies began in 2007 and has grown significantly. This showcases Syngene's ability to meet international quality standards and regulatory requirements.
Syngene International has collaboration with Amgen and another major global biotechnology company. This further strengthens its international credentials. The company operates a dedicated R&D centre for Amgen, providing integrated drug discovery and development services. This partnership demonstrates Syngene's capability to handle complex research projects and meet the exacting standards of international clients.
The company's relationship with GlaxoSmithKline (GSK) represents another significant international partnership. Through this collaboration, Syngene provides various research and development services. This contributes to GSK's global drug discovery and development programs. These partnerships with leading pharmaceutical companies have helped Syngene build a strong reputation in the global CRAMS market.
Syngene's international operations are supported by its state-of-the-art facilities in India that conform to global standards. The company's research and manufacturing facilities are certified by international regulatory authorities. These authorities include the US FDA and EMA (European Medicines Agency), which enables the company to serve its clients worldwide. This regulatory compliance has been crucial in attracting and retaining international clients.
The company has also developed expertise in various therapeutic areas that are relevant to global markets. These therapeutic areas include oncology, cardiovascular, diabetes, and inflammatory diseases. This broad therapeutic coverage allows Syngene to cater to diverse international client requirements and participate in global drug discovery and development programs.
Syngene's international business model is built on providing integrated services across the drug discovery and development value chain. The company offers end-to-end solutions from early-stage research to commercial manufacturing. These solutions appeal to international clients looking to outsource their R&D and manufacturing needs. This comprehensive service offering has helped Syngene secure long-term contracts with international clients.
The company's scientific talent pool comprises highly qualified researchers and scientists. Many of these researchers and scientists have international exposure and experience, which further strengthens the company's ability to serve global clients. This expertise allows Syngene to undertake complex research projects and deliver results that meet international standards.
Syngene International's success in building a strong international presence can be attributed to its focus on quality, regulatory compliance, comprehensive service offerings, and strong client relationships. The company has successfully positioned itself as a reliable partner for global pharmaceutical and biotechnology companies. This is evidenced by its long-term partnerships with industry leaders like Bristol Myers Squibb, Amgen, and GSK.
Plus, the company is committed to maintaining high-quality standards and investing in cutting-edge facilities. This suggests that it will continue to strengthen its position in the global CRAMS market. The company's international focus has helped to grow its business. Also, this has also contributed to establishing India as a preferred destination for pharmaceutical research and manufacturing services.
Know More
